Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000799131 | SCV000938781 | uncertain significance | Cohen syndrome | 2022-02-23 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 840 of the VPS13B protein (p.Val840Met). This variant is present in population databases (rs141694201, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 645108). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV000799131 | SCV002079518 | uncertain significance | Cohen syndrome | 2021-05-05 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004742641 | SCV005347207 | uncertain significance | VPS13B-related disorder | 2023-12-19 | no assertion criteria provided | clinical testing | The VPS13B c.2518G>A variant is predicted to result in the amino acid substitution p.Val840Met. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0018% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |